NEWS HIGHLIGHTSMedia Articles Related to Anturane (Sulfinpyrazone)
In Gout Flare-Ups, The Big Toe Isn't The Biggest Culprit - Other Joints Tied To Higher Risk
Source: Arthritis / Rheumatology News From Medical News Today [2013.06.13]
The painful rheumatic condition gout is often associated with the big toe, but it turns out that patients at highest risk of further flare-ups are those whose gout first involved other joints, such as a knee or elbow, Mayo Clinic has found. The study is among several that Mayo researchers are presenting in Madrid at the European League Against Rheumatism's annual meeting...
Will New Gout Findings Get a Toehold?
Source: MedicineNet Arthritis Specialty [2013.06.12]
Title: Will New Gout Findings Get a Toehold?
Category: Health News
Created: 6/12/2013 10:35:00 AM
Last Editorial Review: 6/12/2013 12:00:00 AM
Vitamin C Does Not Lower Uric Acid Levels In Gout Patients
Source: Gout News From Medical News Today [2013.05.16]
Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout...
UL Medical School Researchers Find Increased Death Risk In Patients Suffering From Gout And Elevated Uric Acid Levels
Source: Gout News From Medical News Today [2013.05.02]
A new study led by researchers at the Graduate Entry Medical School (GEMS), University of Limerick (UL) has found that people suffering from gout and elevated serum uric acid have significantly increased risks of death. In their study, individuals with a diagnosis of gout experienced a 42 % higher risk of death from all causes and a 58% higher risk of cardiovascular death...
Shedding Light On Gout: Repair Of Protein Pump Possible
Source: Gout News From Medical News Today [2013.04.10]
Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream. By comparing this protein pump to a related protein involved in cystic fibrosis, the researchers also identified a compound that partially repairs the pump in laboratory tests...
Published Studies Related to Anturane (Sulfinpyrazone)
The effect of sulfinpyrazone on treadmill exercise-induced angina pectoris. [1993]
Suspecting that platelet thromboemboli could play a role in the pathogenesis of myocardial ischemia, we have done a random-order, double-blind, crossover study of the effect of the platelet-active drug sulfinpyrazone on treadmill exercise-induced angina pectoris in 30 men with coronary artery disease.
Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. [2000.12]
BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult. Because of the myelotoxicity of combined allopurinol and azathioprine, we tested sulfinpyrazone... However, this drug reduced CsA levels, thus the risk of rejection is present.
Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. [1998.08]
The protective activity of the phenylbutazone derivative, sulfinpyrazone on retinal lesions has been assessed in rabbits with severe streptozotocin-induced diabetes. Sulfinpyrazone (8 mg kg-1 per day per os) was administered in diabetic animals in two different experimental procedures: for 135 days in a preventive approach (beginning on the day of initial hyperglicaemia); and for 30 days in a therapeutic approach (beginning on the day of appearance of severe retinal damage)...
Acute renal failure due to sulfinpyrazone. [1998.05]
A case of sulfinpyrazone-associated acute renal failure is reported. Sulfinpyrazone can cause reversible acute renal failure from acute tubular necrosis in patients with volume depletion.The patients at risk for acute renal failure due to sulfinpyrazone are those who have intravascular volume depletion as sensed by the kidneys.
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. [1991.06.15]
We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis... A relatively high rate of complications, particularly mild gastrointestinal bleeding, was noted in patients on aspirin/sulfinpyrazone that could not be predicted on the basis of pre-treatment hemostatic test results.
|
